CRVS Key Statistics, Chart & Performance
The current stock price of CRVS is 20.82 USD. In the past month the price increased by 211.68%. In the past year, price increased by 299.62%.
CRVS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CRVS. When comparing the yearly performance of all stocks, CRVS is one of the better performing stocks in the market, outperforming 99.28% of all stocks.
CRVS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CRVS. No worries on liquidiy or solvency for CRVS as it has an excellent financial health rating, but there are worries on the profitability.
CRVS Financial Highlights
Over the last trailing twelve months CRVS reported a non-GAAP Earnings per Share(EPS) of -0.19. The EPS increased by 78.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.73% | ||
| ROE | -21.01% | ||
| Debt/Equity | 0 |
CRVS Forecast & Estimates
13 analysts have analysed CRVS and the average price target is 15.64 USD. This implies a price decrease of -24.88% is expected in the next year compared to the current price of 20.82.
CRVS Ownership
CRVS Latest News, Press Relases and Analysis
CRVS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.95 | 383.716B | ||
| AMGN | AMGEN INC | 16.25 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 16.37 | 181.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.11 | 119.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.68 | 81.459B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.14 | 46.497B | ||
| INSM | INSMED INC | N/A | 32.511B | ||
| NTRA | NATERA INC | N/A | 28.376B | ||
| BIIB | BIOGEN INC | 12.01 | 27.206B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.38 | 20.78B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CRVS
Company Profile
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. The company is headquartered in Burlingame, California and currently employs 31 full-time employees. The company went IPO on 2016-03-23. The firm is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
Company Info
CORVUS PHARMACEUTICALS INC
863 Mitten Rd Ste 102
Burlingame CALIFORNIA 94010 US
CEO: Richard A. Miller
Employees: 31
Phone: 16509004520
CORVUS PHARMACEUTICALS INC / CRVS FAQ
What does CRVS do?
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. The company is headquartered in Burlingame, California and currently employs 31 full-time employees. The company went IPO on 2016-03-23. The firm is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
Can you provide the latest stock price for CORVUS PHARMACEUTICALS INC?
The current stock price of CRVS is 20.82 USD. The price decreased by -2.44% in the last trading session.
What is the dividend status of CORVUS PHARMACEUTICALS INC?
CRVS does not pay a dividend.
How is the ChartMill rating for CORVUS PHARMACEUTICALS INC?
CRVS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is CORVUS PHARMACEUTICALS INC (CRVS) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CRVS.
What is the market capitalization of CRVS stock?
CORVUS PHARMACEUTICALS INC (CRVS) has a market capitalization of 1.55B USD. This makes CRVS a Small Cap stock.
What is the next earnings date for CRVS stock?
CORVUS PHARMACEUTICALS INC (CRVS) will report earnings on 2026-03-23, after the market close.